| Autor: |
Hong Lou, Eduardo Gharzouzi, Sarita Polo Guerra, Joël Fokom Domgue, Edmundo Torres-Gonzalez, Julie Sawitzke, Guillermo Villagran, Lisa Garland, Joseph Boland, Sarah Wagner, Joanna Martinez, Héctor Rosas, Jami Troxler, Heidi McMillen, Bailey Kessing, Enrique Alvirez, Miriam Castillo, Hesler Morales, Victor Argueta, Andert Rosingh, Femke J.H.B. van Aerde-van Nunen, Herbert M. Pinedo, Griselda Lopez, Mark Schiffman, Michael Dean, Roberto Orozco |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| Předmět: |
|
| DOI: |
10.1101/134775 |
| Popis: |
BackgroundA low cost and accurate method for detecting high-risk (HR) HPV is important to permit HPV testing for cervical cancer prevention. We validated a low-cost commercially available HPV method (H13, Hybribio, Hong Kong) and determined the distribution of HPV infections in over 1717 cancer-free women in Guatemala.MethodsH13 results were compared with two more established HPV tests: (Xpert™ (Cepheid) and SPF10-LIPA25™ (DDL)) in 40 mainly known positive specimens. HR-HPV was detected in cervical samples from 1717 cancer-free women receiving Pap smears using the Hybribio™ realtime PCR assay of 13 HR types. Selected HPV positive samples were sequenced to determine viral type.ResultsThe Hybribio H13 Assay showed 93% identical results with Xpert, and 89% with SPF10-LIPA25. A total of 13% (226/1717) of women tested HPV+. The highest prevalence was found in younger women (ConclusionsThe Hybribio Assay was low cost, and accurate in testing for HR-HPV infection. As in most places, HPV16 was the most prevalent HR type in Guatemala and the age-specific prevalence curve peaked in younger ages.HighlightsA low cost and accurate method, Hybribio Assay, could be used for CC testing in low income regions.A total of 13% of cancer-free women were HPV+ and positivity was associated with younger age (HPV16 was the major prevalent type. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
